Reported Earlier, Medtronic's PulseSelect PFA System Shows 98% Success in Treating Atrial Fibrillation, Study Reveals High Lesion Durability
Reported Earlier, Medtronic's PulseSelect PFA System Shows 98% Success in Treating Atrial Fibrillation, Study Reveals High Lesion Durability
早前报道，美敦力的PulseSelect PFA系统在治疗心房颤动方面显示出98%的成功率，研究显示病变持久性高
Medtronic(MDT.US), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstrated durable isolation in 98% of pulmonary veins (PV) and 96% of patients had all veins isolated.
美敦力(MDt.US)作为医疗科技领域的全球领导者，今天宣布了临床研究结果的发布，展示了脉冲选择脉冲场消融(PFA)系统治疗房颤(Afib)时耐久性损伤形成的高比例。使用脉冲选择PFA系统进行消融约两个月后进行的侵入性重映射显示，98%的肺静脉（PV）实现了耐久性隔离，96%的患者所有静脉被隔离。
Results were presented as a late breaking clinical trial at the Asia Pacific Heart Rhythm Society (APHRS) meeting in Sydney, Australia.
结果作为一项迟发的临床试验在亚太心脏心律协会（APHRS）会议上在澳洲悉尼报告。
"Real-world evidence on chronic lesion formation and durability is critical as use...
"随着PFA用于治疗房颤的...
登录免费看全文
登录/注册